

Commercial Recruitment to Target

| Research Ethics Committee Reference | Study Title | Recruitment Target | Recruitment End Date | Study Status | Performance Against Target |
|-------------------------------------|---|--------------------|----------------------|-----------------------------|----------------------------|
| 12/SC/0318 | SWAP 2: A Pharmacodynamic Evaluation of Switching from Ticagrelor to Prasugrel (CS747S-B-U4003) | 5 | 11/01/2013 | Closed - Follow Up Complete | Target Not Met |
| 12/LO/0050 | H6D-MC-LVIG: Study of Tadalafil in Children with Pulmonary Arterial Hypertension (MCRN159) | 2 | 24/01/2013 | Closed - Follow Up Complete | Target Not Met |
| 11/LO/1728 | MCRN128 (CL2-16257-090) | 2 | 31/01/2013 | Closed - Follow Up Complete | Target Not Met |
| 12/LO/0372 | ALLERGAN DME 206207-024 | 4 | 01/02/2013 | Closed - In Follow Up | Target Not Met |
| 10/H0606/78 | CCRN 378 (Crohn's) | 6 | 28/02/2013 | Closed - Follow Up Complete | Target Not Met |
| 11/LO/1733 | INTERNATIONAL (NCRN 336): BITE - ALL MT103-211: Phase II Trial with Blinatumomab in relapsed/refractory B-precursor ALL | 2 | 28/02/2013 | Closed - Follow Up Complete | Target Met |
| 11/LO/0886 | (CCRN 311)ATOMIC-HF - Phase 2 Study with AMG 423 in Acute Heart Failure | 4 | 30/03/2013 | Closed - In Follow Up | Target Not Met |
| 11/H0606/6 | Crohn's Disease Maintenance Trial - CCX114157 (CCRN 381) | 3 | 31/03/2013 | Closed - Follow Up Complete | Target Not Met |
| 12/SC/0024 | CRYSTAL CRFB002E2401 | 5 | 31/03/2013 | Closed - In Follow Up | Target Met |
| 12/SC/0469 | EFC12492: Odyssey FH I | 5 | 08/04/2013 | Closed - In Follow Up | Target Met |
| 12/EE/0499 | MK-5172 with peg-IFN and RBV in HCV Infected Subjects (MK5172-038) | 5 | 09/05/2013 | Closed - In Follow Up | Target Not Met |
| 12/SC/0025 | BRIGHTER (CRFB002E2402) | 5 | 31/05/2013 | Closed - In Follow Up | Target Met |
| 11/LO/0743 | PARACHUTE III | 4 | 01/06/2013 | Closed - In Follow Up | Target Not Met |
| 11/LO/1408 | ABSORB II | 10 | 30/06/2013 | Closed - In Follow Up | Target Met |

Commercial Recruitment to Target

| Research Ethics Committee Reference | | Study Title | Recruitment Target | Recruitment End Date | Study Status | Performance Against Target |
|-------------------------------------|--|--|--------------------|----------------------|-----------------------------|----------------------------|
| 12/LO/0582 | | GO27819 Phase II Study of MetMab in Patients with Recurrent Glioblastoma | 12 | 30/06/2013 | Closed - In Follow Up | Target Not Met |
| 12/SC/0540 | | BI 207127 in Treatment-Naïve Patients with HCV | 5 | 30/06/2013 | Closed - In Follow Up | Target Not Met |
| 12/NE/0266 | | CCRN 427 (Crohn's extension) | 3 | 05/07/2013 | Closed - Follow Up Complete | Target Not Met |
| 10/H1002/1 | | MCRN063 (TAK-491_109) | 3 | 31/07/2013 | Closed - Follow Up Complete | Target Not Met |
| 10/H1008/83 | | MCRN090 (20090005) | 1 | 31/07/2013 | Suspended | Target Not Met |
| 11/SC/0177 | | CCRN 530 (Hep C) | 1 | 31/08/2013 | Closed - In Follow Up | Target Met |
| 11/LO/0608 | | NCRN322 TERRAIN: MDV3100 (ASP9785) vs. Bicalutamide Metastatic Prostate Cancer | 5 | 31/08/2013 | Closed - In Follow Up | Target Met |
| 11/SC/0326 | | UNITI 1 | 5 | 31/08/2013 | Closed - In Follow Up | Target Not Met |
| 10/H1308/65 | | EPI-STREP: NTHi and chronic cough epidemiology study in the UK | 50 | 31/08/2013 | Withdrawn | Target Not Met |
| 12/SC/0384 | | V72P12E2 - A new vaccine against meningitis groupB: A second follow-on | 52 | 31/08/2013 | Closed - Follow Up Complete | Target Met |
| 12/LO/1156 | | NCRN469 COMET 1: Cabozantinib vs Prednisone in mCRPC after prior therapy | 5 | 16/09/2013 | Closed - In Follow Up | Target Not Met |
| 09/H0406/106 | | NCRN069 ORCHARRD - Ofatumumab vs Rituximab followed by ASCT in DLBCL | 5 | 31/10/2013 | Closed - In Follow Up | Target Not Met |
| 11/LO/1023 | | CCRN 492 (Branch retinal vein occlusion) | 10 | 31/10/2013 | Closed - In Follow Up | Target Met |
| 11/LO/0619 | | NCRN325 HOPE: E7080 +/- Everolimus in mRCC following one prior VEGF-targeted treatment | 4 | 31/10/2013 | Closed - In Follow Up | Target Not Met |
| 12/LO/0250 | | MATISSE STUDY | 6 | 31/10/2013 | Closed - Follow Up Complete | Target Met |

Commercial Recruitment to Target

| Research Ethics Committee Reference | Study Title | Recruitment Target | Recruitment End Date | Study Status | Performance Against Target |
|-------------------------------------|---|--------------------|----------------------|-----------------------------|----------------------------|
| 11/LO/1810 | DEFLECT I Trial | 6 | 31/10/2013 | Closed - Follow Up Complete | Target Met |
| 13/EM/0084 | CCRN 2010 - Baxter 261201: PEGylated Recombinant Factor VIII in Severe Hemophilia A | 2 | 31/10/2013 | Closed - In Follow Up | Target Met |
| 12/SW/0228 | A randomized control trial of non-invasive ventilation during an exercise programme following acute acidotic exacerbation of COPD in hospital and follow-up use at home: feasibility of using the Trilogy Ventilator. | 37 | 30/11/2013 | Open | Still open to Recruitment |
| 12/LO/0080 | OCTAVE A3921095: 007: Oral CP690,550 as an Induction Therapy for Ulcerative Colitis | 5 | 30/11/2013 | In set up | Still open to Recruitment |
| 12/LO/0081 | OCTAVE A3921096: 008: Oral CP-690, 550 as Maintenance Therapy for Ulcerative Colitis | 3 | 30/11/2013 | In set up | Still open to Recruitment |
| 12/LO/0082 | OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of Ulcerative Colitis | 5 | 30/11/2013 | In set up | Still open to Recruitment |
| 10/H0808/138 | CCRN 499 (CV) | 10 | 30/12/2013 | Open | Still open to Recruitment |
| 10/H1308/84 | NCRN252 - Nilotinib in paediatric Ph+ CML/ALL | 1 | 31/12/2013 | Open | Still open to Recruitment |
| 10/H0406/90 | OSI-906: Phase 2 Study of OSI906 and Erlotinib in Patients with Advanced NSCLC and Erlotinib in Patients with Advanced NSCLC | 3 | 31/12/2013 | Closed - In Follow Up | Target Not Met |
| 10/H0711/66 | BLAST NCRN170 | 2 | 31/12/2013 | Open | Still open to Recruitment |
| 11/VM/0279 | NECTAR-HF Research Study | 6 | 31/12/2013 | Closed - In Follow Up | Target Not Met |
| 12/EM/0018 | CCRN 738 (Post-Myocardial Infarction) | 8 | 31/12/2013 | Withdrawn | Target Not Met |
| 12/LO/1358 | NCRN532 (TAS 102) | 7 | 31/12/2013 | Closed - In Follow Up | Target Not Met |
| 13/SW/0072 | FTY720D2205 (CCRN 2149) | 3 | 31/12/2013 | Withdrawn | Target Not Met |
| 13/SC/0171 | VX12-809-104 Lumacaftor + Ivacaftor in Cystic Fibrosis | 3 | 31/12/2013 | Closed - In Follow Up | Target Not Met |

Commercial Recruitment to Target

| Research Ethics Committee | | Recruitment Target | Recruitment End Date | Study Status | Performance Against Target |
|---------------------------|---|--------------------|----------------------|--------------|----------------------------|
| Reference | Study Title | | | | |
| 12/EE/0400 | Extension study of GS-7977 in patients with HCV infection (GS-US-334-0109) | 5 | 27/01/2014 | Open | Still open to Recruitment |
| 12/SC/0434 | (MCRN194) DPM-CF-204 mannitol in CF aged 6-17 | 4 | 03/02/2014 | Open | Still open to Recruitment |
| 12/SW/0084 | LFG316 MFC | 5 | 28/02/2014 | Open | Still open to Recruitment |
| 13/SC/0213 | ACT IV Study - Protocol CDX110-04 | 6 | 03/03/2014 | Open | Still open to Recruitment |
| 13/LO/0418 | SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228) | 2 | 15/03/2014 | Open | Still open to Recruitment |
| 13/EM/0254 | CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302) | 2 | 28/03/2014 | Open | Still open to Recruitment |
| 13/NW/0464 | Pharmacokinetic and Pharmacodynamic Trial of IDN6556 | 4 | 30/03/2014 | Open | Still open to Recruitment |
| 11/WA/0363 | A Phase 2 MultiCenter, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | 1 | 31/03/2014 | Open | Still open to Recruitment |
| 13/NE/0294 | ROCHE PHASE I SINGLE ASCENDING DOSE Study of RO6867461 in wAMD | 5 | 30/04/2014 | Open | Still open to Recruitment |
| 12/EE/0257 | MK-5172 + MK-8742 + Ribavirin in genotype 2 Hepatitis C Infection (MK5172-047) | 1 | 02/06/2014 | Open | Still open to Recruitment |
| 11/SC/0327 | CCRN 601 (Crohn's Disease) | 5 | 30/06/2014 | Open | Still open to Recruitment |
| 11/LO/1226 | CCRN 592 (Uveitis) | 10 | 30/06/2014 | Open | Still open to Recruitment |
| 12/SC/0502 | Pfizer B1181003 Clinical Study of RN6G (PF-04382923) | 3 | 30/06/2014 | Withdrawn | Target Not Met |
| 12/NW/0585 | Trastuzumab Emtansine (TDM1) (GATSBY) | 2 | 31/07/2014 | Open | Still open to Recruitment |
| 13/YH/022 | MCI-196-E16 | 2 | 31/07/2014 | Open | Still open to Recruitment |
| 12/WA/0058 | NCRN398 IMAGE: Observational Study in Patients with Unresectable or Metastatic Melanoma | 10 | 31/07/2014 | Open | Still open to Recruitment |
| 13/LO/0615 | ASTEX SGI-110: A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects with Platinum-Resistant Recurrent Ovarian Cancer | 3 | 31/07/2014 | Open | Still open to Recruitment |
| 10/H0406/46 | ABBOTT 880 CCRN 282 (Inactive uveitis) | 4 | 17/08/2014 | Open | Still open to Recruitment |
| GTAC185 | PROSTVAC | 5 | 31/08/2014 | Open | Still open to Recruitment |

Commercial Recruitment to Target

| Research Ethics Committee | | Recruitment Target | Recruitment End Date | Study Status | Performance Against Target |
|---------------------------|--|--------------------|----------------------|-----------------------------|----------------------------|
| Reference | Study Title | | | | |
| 10/H0406/45 | ABBOTT 877 CCRN 281 (Active uveitis) | 4 | 16/09/2014 | Open | Still open to Recruitment |
| 10/H0406/47 | ABBOTT 327 CCRN 283 (LT uveitis) | 8 | 30/09/2014 | Open | Still open to Recruitment |
| 12/SC/0309 | INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic Leukaemia | 1 | 28/10/2014 | Open | Still open to Recruitment |
| 13/LO/0945 | MCRN 2419: KOGNITO (Kuvan®'s effect on the cOGNITION of children with phenylketonuria) | 2 | 31/10/2014 | Open | Still open to Recruitment |
| 13/YH/0021 | MCI-196-E15 Extension Study Evaluating Colestilan | 2 | 31/12/2014 | Open | Still open to Recruitment |
| 12/NW/0367 | MCRN177 (BEL114055) | 1 | 31/12/2014 | Open | Still open to Recruitment |
| 12/LO/1876 | COBRIM - GO28141 | 5 | 31/12/2014 | Closed - In Follow Up | Target Not Met |
| 12/NW/0641 | NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma | 8 | 31/12/2014 | Open | Still open to Recruitment |
| 12/WA/1064 | ZEST | 4 | 31/12/2014 | Open | Still open to Recruitment |
| 13/EE/0263 | MASTER II Trial | 20 | 31/12/2014 | Open | Still open to Recruitment |
| 13/LO/0150 | RESORCE: The regorafenib in patients with hepatocellular carcinoma | 2 | 01/02/2015 | Open | Still open to Recruitment |
| 10/H1003/120 | Intravenous zanamivir versus oral oseltamivir in hospitalised influenza (NAI114373 - ZORO) | 2 | 27/02/2015 | Open | Still open to Recruitment |
| 13/YH/0136 | CCRN 2173 (AI Liver Decompensation) | 2 | 30/03/2015 | Open | Still open to Recruitment |
| 11/NW/0298 | Gallium | 14 | 31/03/2015 | Open | Still open to Recruitment |
| 12/LO/1090 | YO28322 | 4 | 01/06/2015 | Open | Still open to Recruitment |
| 13/ES/0005 | AZA-MDS-003 | 2 | 30/06/2015 | Open | Still open to Recruitment |
| 13/LO/1283 | NCRN605 - TAMIGA | 6 | 30/10/2015 | Open | Still open to Recruitment |
| 12/LO/0482 | PERUSE (MO28047): Global safety study with pertuzumab in Her2+ advanced BC | 5 | 31/03/2016 | Closed - Follow Up Complete | Target Not Met |
| 13/LO/0520 | OCTAVE, Ranibizumab in neovascular age-related macular degeneration(CRFB002A2405) | 4 | 16/04/2016 | Open | Still open to Recruitment |
| 13/NW/0321 | MCRN234 (WA28118) | 2 | 30/04/2016 | Closed - In Follow Up | Target Met |

Commercial Recruitment to Target

| Research Ethics Committee Reference | | Study Title | Recruitment Target | Recruitment End Date | Study Status | Performance Against Target |
|-------------------------------------|--|-------------|--------------------|----------------------|-----------------------|----------------------------|
| 13/NW/0320 | MCRN235 (WA28117) | | 2 | 30/04/2016 | Closed - In Follow Up | Target Met |
| 13/WA/0101 | CCRN 2088 (Pneumonia) | | 6 | 30/04/2016 | Open | Still open to Recruitment |
| 13/EM/0012 | NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with malignant melanoma | | 1 | 30/06/2016 | Open | Still open to Recruitment |
| 09/H0802/125 | MCRN062 (NAI113678) | | 1 | 27/01/2017 | Open | Still open to Recruitment |
| 11/LO/0923 | NCRN259 HERBY - Bevacizumab in paediatric high grade glioma | | 3 | 22/08/2017 | Open | Still open to Recruitment |
| 11/SC/0329 | CCRN 602 (Crohn's disease) | | 5 | 31/10/2017 | Open | Still open to Recruitment |
| 09/H0718/18 | BERNIE: Bevacizumab and standard chemotherapy in childhood soft-tissue sarcoma | | 4 | 07/11/2018 | Closed - In Follow Up | Target Met |